Relmada Therapeutics, Inc. RLMD
3.83
0.02
0.52%
as of 25 Sep
- Market cap
- $406.4M
- P/E
- 0.0×
Follow RLMD
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (55.66%) | (48.83%) | (94.05%) | (196.79%) |
+8 more TTM periods Free account |
|
| (51.57%) | (44.77%) | (82.08%) | (159.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(29.26%) | (26.47%) | (65.54%) | (581.23%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.41) | (0.49) | (1.16) | (1.20) | |
Free Cash Flow |
(45.99) | (42.79) | (45.79) | (39.99) | |
| Other line items | |||||
Cash ROIC |
(10.84%) | (9.45%) | (25.51%) | (171.25%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.73 | 0.80 | 0.71 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.49) | (1.16) | (1.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates